Please login to the form below

constipation

This page shows the latest constipation news and features for those working in and with pharma, biotech and healthcare.

dose. The most common side effects were constipation, nausea, dry mouth, dyspepsia and vomiting.

Ardelyx gets second kidney disease trial win for tenapanor

Shares in Ardelyx rocketed 72% on the back of the new study on the prospect of a second indication for tenapanor to follow constipation associated with IBS, which is under review
China approves Ironwood Pharma’s IBS treatment

Approval by China’s NMPA for adults with irritable bowel syndrome with constipation (IBS-C) opens up the country's huge market to the treatment. ... This approval is incredibly important as it brings a new option to treat some of the bothersome
Shire bags US approval for constipation drug Motegrity

Approval is boost as Takeda takeover nears completion. Shire has the US approval it needs for Motegrity, a drug for chronic idiopathic constipation (CIC) that will compete with drugs like
Immunology keeps Shire figures solid as Takeda takeover nears

HAE, prucalopride (SHP555) for chronic idiopathic constipation, and calaspargase pegol (SHP663) for the treatment of acute lymphoblastic leukaemia (ALL).
Mallinckrodt pays $1.2bn for Sucampo Pharma

As 2017 drew to a close, Mallinckrodt signed a deal to buy Sucampo Pharma of the US - and its constipation drug Amitizia - for $1.2bn. ... Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic

More from news
Approximately 8 fully matching, plus 66 partially matching documents found.

Case study: What we're made of

If we don’t drink enough water, it can lead to headaches, constipation, tiredness and more serious problems, such as urinary infections and kidney disease.
Erectile dysfunction, constipation, vaginal dryness and other laughing matters

Diarrhoea, constipation, flatulence, leaky bladder, vaginal dryness - it’s all fertile territory.
Taking a lean and careful approach

His pioneering research culminated in the drug, Trulance, which has received FDA approval and is being used to treat irritable bowel syndrome and chronic constipation.
Deal Watch March 2016

$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.
Oral biologics delivery still elusive

years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Ironwood appoints Edward Owens to board

irritable bowel syndrome and constipation.
Norgine’s Karen Hockey promoted to head of global marketing

Appointment follows nearly two years as global brand manager for constipation treatment Movicol. ... Hockey's promotion comes after nearly two years as global brand manager for constipation treatment Movicol since joining Norgine in 2011.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Add my company

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...